This episode is a recording of the White Paper: Perspective on Aducanumab’s Nov. 6 Advisory Committee, read by Shanti Skiffington.

This week Shanti and Eliot talk to Dr. Scott Napper, Professor of Biochemistry, Microbiology & Immunology at the University of Saskatchewan, about the future of an Alzheimer’s Vaccine.

On today's episode, Shanti and Eliot talk to Dr. Neil Cashman about a vaccine for Alzheimer’s disease and how that fits into the detection, treatment, and prevention of the disease.

Shanti and Eliot talk to Dr. Josè Luis Molinuevo of the BarcelonaBeta Brain Research Center about his experience at AAIC, and the presentation he gave on biomarkers.

This week, Shanti and Eliot talk to founder and CEO of Unlearn, Charles Fisher. They discuss how artificial intelligence can effect Alzheimer's drug research.

Episode Notes Shanti and Elliot talk to Dr. James Kupiec about a diagnostics test for Alzheimer's disease.

Episode Notes Shanti and Elliot discuss recent developments in antibody testing for Covid-19

Elliot and Shanti talk to Johanne Kaplan about a new way to attack ALS and other protein misfolding diseases,

This week Shanti and Elliot discuss Intrabodies with Dr. Johanne Kaplan

Dr. Jim Kupiec explains why there is nothing to worry about regarding the recent news about aducanumab.

Shanti and Elliot announce that ProMIS is beginning to develop a test for Covid-19. They discuss how ProMIS can leverage its existing expertise.

We are re-releasing a popular episode about Biomarkers and how they work!

Shanti and Elliot talk to Dr. José Luis Molinuevo of the BarcelonaBeta Brain Research Center on the Future of Alzheimer's Disease

Dr. Stephen Salloway and Dr. James Kupiec reflect on Aducanumab, the exciting progress that has been made in the AD research community over the last 20 years, and the future of AD research.

This week Shanti and Elliot talk to Dr. Sharon Cohen, director of Toronto Memory Program. They discuss the recent news surrounding aducanumab, as well as Dr. Cohen's recent trip to CTAD.

This week Shanti and Elliot discuss the data behind Biogen's recent decision to revive their Aducanumab study.

This week Shanti and Johanne discuss the recent news coming out of Biogen and how Neuroinflammation relates to Alzheimer's.

This week Shanti and Elliot talk to Dr. Lary Walker, a research professor at Emory University. They discuss what Alzheimer’s, Parkinson’s and more have in common.

This week Shanti and Elliot are joined by Brain Canada's CEO Inez Jabalpurwala. They discuss the wonderful work that Brain Canada has been doing, and the next steps in the search for a cure for Alzheimer's, Parkinson's and other diseases.

This week Shanti and Elliot discuss Multiple System Atrophy, prions and how greater understanding of each can help other neurodegenerative diseases.

This week Shanti is joined by Dr. James Kupiec, Chief Medical Officer at ProMIS Neurosciences. Shanti and Dr. Kupiec do a deep dive on Biomarkers and discuss recent research coming out of AAIC.

Elliot is back to discuss the TDP43 protein, which has been implicated in the development of a recently discovered form of dementia as well as ALS. Shanti and Elliot talk about why TDP43 is important, and the efforts to neutralize the misfolded protein in the brain before it can destroy brain cells.

This week Shanti and Dr. Johanne Kaplan recap AAIC 2019 and discuss the exciting data that came out of the conference. For more information check out https://promisneurosciences.com/

This week Shanti and Johanne preview AAIC and discuss what the hot topics at the conference are expected to be.

This week Shanti discusses some of the most exciting news coming out of the recent 2019 Keystone Symposia with Dr. Johanne Kaplan.

Shanti is joined by Dr. Johanne Kaplan, the Chief Development Officer at ProMIS Neurosciences. The two discuss Dr. Kaplan's career, and the current challenges researchers must tackle as they continue their search for a way to stop Alzheimer's disease. The two also discuss Dr. Kaplan's recent paper on the importance of selectivity in drug development for Alzheimer's.

Toxic tau and amyloid-beta are the two most validated drug targets for an Alzheimers disease therapy. Elliot and Shanti discuss tau, its role as a root cause of Alzheimer's disease and its involvement in 80 other diseases known as tauopathies.

Dr. Goldstein and Shanti breakdown the news of the week. This week they discuss two major late-stage failures for promising Alzheimer's drugs, a new syndrome that is similar to Alzheimer's, and some important biomarker developments.

This is part two of our exploration of biomarkers. Elliot and Shanti discuss how biomarkers work and how they will play a critical role in the future of drug development for the various brain-wasting diseases.

Dr. Goldstein and Shanti discuss why biomarkers are becoming increasingly important in the medical community. They also discuss how biomarkers are uniquely important in the quest for a cure for Alzheimer's.

This week Dr. Goldstein and Shanti discuss Parkinson's disease. They discuss the underlying cause of Parkinson's, treatment options, side effects and the connection between Parkinson's and Alzheimer's

This week our hosts Dr. Elliot Goldstein MD and Shanti Skiffington provide a summary of the current efforts to find a cure for Alzheimer's disease.